Search results
Results From The WOW.Com Content Network
Athersys (ATHX) gains on encouraging results from its exploratory study on the intravenous administration of MultiStem cell therapy to treat patients suffering from ARDS.
For premium support please call: 800-290-4726 more ways to reach us
For premium support please call: 800-290-4726 more ways to reach us
Finance. Yahoo! Yahoo! Finance is a media property that is part of the Yahoo! network. It provides financial news, data and commentary including stock quotes, press releases, financial reports, and original content. It also offers some online tools for personal finance management. In addition to posting paid partner content from other web sites ...
While a mid-stage/late-stage study evaluating Athersys' (ATHX) stem cell treatment for ischemic stroke misses out on its primary endpoint, top-line data shows evidence of therapeutic impact.
It now expects earnings per share between $2.15 and $2.35. That's up from previous guidance of between $2.05 and $2.25. The company's dividend is $0.42 per share quarterly, or $1.68 annually. It's ...
Click here for in-depth analysis of the latest stock market news and events moving stock prices. Read the latest financial and business news from Yahoo Finance. Show comments. Advertisement ...
Click the Home button on your remote. Go to the upper left-hand corner, select Guide, and click on Yahoo Finance, channel 4201. finance.yahoo.com and Yahoo Finance app. You can also always find ...